Selpercatinib (Retsevmo, Eli Lilly) as monotherapy is indicated for 'the treatment of adults and adolescents 12 years and older with:
advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate)
advanced RET-mutant medullary thyroid cancer (MTC)'.
The dosage schedule is available in the summary of product characteristics for selpercatinib.
The list price is £2,184 for 56 capsules of 40 mg selpercatinib and £4,368 for 56 capsules of 80 mg (excluding VAT; BNF online accessed August 2024).
The company has a commercial arrangement. This makes selpercatinib available to the NHS with a discount. The size of the discount is commercial in confidence.